PharmaTimes -
July/August 2022

Altogether now

Perhaps the one ‘silver lining’ from the healthcare tumult and pandemic chaos of the past couple of years was a demonstration of unity between pharma, public health institutions and – pivotally – the wider public. This cooperation was absolutely fundamental on the relative return to normality which we are now relishing.

In many ways, it was a unique demonstration of what happens when an often-misunderstood industry is rapidly demystified by chance and circumstance. In the case of pharma, it was a stark example of trust engendered at hyper-speed. Indeed, history will witness that the take-up of the vaccine was a pivotal moment when all things seem possible.

Make no mistake, pharma now has a great opportunity to leverage its new, rebooted relationship with patients – notably through clinical trial redesign, digital health, dynamic communication, healthcare data, diversity & inclusion and the challenge presented by climate change.

These are all the issues that are forming the building blocks of a radical ecosystem in which pharma and patients are co-workers in the increasingly sophisticated and accelerated therapy development process. And at the heart of this is difference. Difference in approach, difference in perspective and, above all, difference in personnel.

It’s a truly transformational time across the pharmaverse and we must make sure that the modern relationships established in recent times are maintained as a force for good.
Many of these era-defining plot points appear in the very pages of this publication – I hope they serve to inspire.

January 2020 - magazine highlights

Thumbnail image for Tomorrow’s world

Tomorrow’s world

As a new era for pharma begins to unfold life sciences pioneers are changing their environments

Thumbnail image for A quiet revolution?

A quiet revolution?

Though barely mentioned in the NHS reform debate, some major changes to Specialised Commissioning are on the way

Thumbnail image for Our imagination

Our imagination

One year on from the launch of the Government’s Life Sciences Vision there is a unique opportunity for the UK to become a genuine industry superpower.

Thumbnail image for Back to life

Back to life

The 2022 International Clinical Researcher of the Year awards recognised our industry’s incredible array of talent – in person!

Thumbnail image for Be patient

Be patient

Awareness raising is key to boosting patient involvement and engendering trust

Thumbnail image for Stark similarities

Stark similarities

How biosimilars support sustainability throughout global healthcare systems and deliver the building blocks for vital healthcare

Thumbnail image for Whole new world

Whole new world

Modern pharma is increasingly about the applying real-world evidence to gene therapies

Thumbnail image for Vision for diversity

Vision for diversity

As we enter a new era of inclusivity are we really doing enough to improve health equity in clinical trials?

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download